Xgene Pharmaceuticals Co. Ltd.and RaQualia Pharma Inc.have entered into a licensing agreement for a novel TRPM8 blocker discovered by RaQualia Pharma.
NDA Application of XG005 will follow a 505(B)(2) regulatory pathway based on FDA’S feedback
May 4, 2019
XGene Pharmaceutical Closed the B Plus
October 25, 2018
XGene Pharmaceutical Closed US$20 Million B Round Financing